Exhibit 10.1
SECURITIES PURCHASE
AGREEMENT
dated January 15,
2009
between
BANK OF AMERICA CORPORATION, as
Issuer
and
UNITED STATES DEPARTMENT OF THE
TREASURY
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
Article I
|
|
|
|
Purchase; Closing
|
|
|
|
|
|
1.1
|
|
Purchase
|
|
1
|
|
|
|
|
|
1.2
|
|
Closing
|
|
1
|
|
|
|
|
|
1.3
|
|
Interpretation
|
|
4
|
|
|
|
Article II
|
|
|
|
Representations and
Warranties
|
|
|
|
|
|
2.1
|
|
Disclosure
|
|
4
|
|
|
|
|
|
2.2
|
|
Representations
and Warranties of the Company
|
|
5
|
|
|
|
Article III
|
|
|
|
Covenants
|
|
|
|
|
|
3.1
|
|
Commercially
Reasonable Efforts
|
|
13
|
|
|
|
|
|
3.2
|
|
Expenses
|
|
13
|
|
|
|
|
|
3.3
|
|
Sufficiency of
Authorized Common Stock; Exchange Listing
|
|
13
|
|
|
|
|
|
3.4
|
|
Certain
Notifications Until Closing
|
|
13
|
|
|
|
|
|
3.5
|
|
Access,
Information and Confidentiality
|
|
14
|
|
|
|
|
|
3.6
|
|
Internal
Controls
|
|
15
|
|
|
|
ARTICLE IV
|
|
|
|
Additional Agreements
|
|
|
|
|
|
4.1
|
|
Purchase for
Investment
|
|
15
|
|
|
|
|
|
4.2
|
|
Legends
|
|
16
|
|
|
|
|
|
4.3
|
|
Certain
Transactions
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
4.4
|
|
Transfer of
Purchased Securities and Warrant Shares; Restrictions on Exercise
of the Warrant
|
|
17
|
|
|
|
|
|
4.5
|
|
Registration
Rights
|
|
17
|
|
|
|
|
|
4.6
|
|
Voting of
Warrant Shares
|
|
29
|
|
|
|
|
|
4.7
|
|
Depositary
Shares
|
|
29
|
|
|
|
|
|
4.8
|
|
Restriction on
Dividends and Repurchases
|
|
30
|
|
|
|
|
|
4.9
|
|
Repurchase of
Investor Securities
|
|
31
|
|
|
|
|
|
4.10
|
|
Executive
Compensation
|
|
32
|
|
|
|
|
|
4.11
|
|
Qualified
Equity Offering
|
|
36
|
|
|
|
|
|
4.12
|
|
Bank Holding
Company Status
|
|
36
|
|
|
|
|
|
4.13
|
|
Certain Tax
Matters
|
|
36
|
|
|
|
Article V
|
|
|
|
Miscellaneous
|
|
|
|
|
|
5.1
|
|
Termination
|
|
36
|
|
|
|
|
|
5.2
|
|
Survival of
Representations and Warranties
|
|
37
|
|
|
|
|
|
5.3
|
|
Amendment
|
|
37
|
|
|
|
|
|
5.4
|
|
Waiver of
Conditions
|
|
37
|
|
|
|
|
|
5.5
|
|
Governing Law:
Submission to Jurisdiction, Etc.
|
|
37
|
|
|
|
|
|
5.6
|
|
Notices
|
|
38
|
|
|
|
|
|
5.7
|
|
Definitions
|
|
38
|
|
|
|
|
|
5.8
|
|
Assignment
|
|
39
|
|
|
|
|
|
5.9
|
|
Entire
Agreement, Etc.
|
|
39
|
|
|
|
|
|
5.10
|
|
Counterparts
and Facsimile
|
|
39
|
|
|
|
|
|
5.11
|
|
Severability
|
|
39
|
|
|
|
|
|
5.12
|
|
No Third Party
Beneficiaries
|
|
39
|
ii
LIST OF ANNEXES
|
|
|
|
|
|
|
|
ANNEX A:
|
|
FORM OF
CERTIFICATE OF DESIGNATIONS FOR PREFERRED STOCK
|
|
|
|
|
ANNEX B:
|
|
FORM OF
WAIVER
|
|
|
|
|
ANNEX C:
|
|
FORM OF
OPINION
|
|
|
|
|
ANNEX D:
|
|
FORM OF
WARRANT
|
LIST OF SCHEDULES
|
|
|
|
|
|
|
|
SCHEDULE A:
|
|
CAPITALIZATION
|
|
|
|
|
SCHEDULE B:
|
|
LITIGATION
|
|
|
|
|
SCHEDULE C:
|
|
COMPLIANCE WITH
LAWS
|
|
|
|
|
SCHEDULE D:
|
|
REGULATORY
AGREEMENTS
|
|
|
|
|
SCHEDULE E:
|
|
OTHER SENIOR
MANAGERS
|
iii
INDEX OF DEFINED
TERMS
|
|
|
|
|
Term
|
|
Location of
Definition
|
|
Affiliate
|
|
5.7(b)
|
|
Agreement
|
|
Preamble
|
|
Appraisal Procedure
|
|
4.9(c)(i)
|
|
Appropriate Federal Banking Agency
|
|
2.2(s)
|
|
Bank Holding Company
|
|
4.12
|
|
Bankruptcy Exceptions
|
|
2.2(d)
|
|
Benefit Plans
|
|
1.2(d)(iv)
|
|
Board of Directors
|
|
2.2(f)
|
|
Bonus Compensation
|
|
4.10(c)(i)
|
|
Bonus Pool Cap
|
|
4.10(c)(i)
|
|
Business Combination
|
|
5.8
|
|
business day
|
|
1.3
|
|
by means of
|
|
4.5(g)(i)
|
|
Capitalization Date
|
|
2.2(b)
|
|
Certificate of Designations
|
|
1.2(d)(iii)
|
|
Charter
|
|
1.2(d)(iii)
|
|
Closing
|
|
1.2(a)
|
|
Closing Date
|
|
1.2(a)
|
|
Code
|
|
2.2(n)
|
|
Common Stock
|
|
Recitals
|
|
Company
|
|
Preamble
|
|
Company Financial Statements
|
|
2.2(h)
|
|
Company Material Adverse Effect
|
|
2.1(a)
|
|
Company Reports
|
|
2.2(i)(i)
|
|
Company Subsidiaries
|
|
2.2(i)(i)
|
|
Company Subsidiary
|
|
2.2(i)(i)
|
|
Company’s knowledge
|
|
5.7(c)
|
|
controlled by
|
|
5.7(b)
|
|
EESA
|
|
1.2(d)(iv)
|
|
ERISA
|
|
2.2(n)
|
|
Exchange Act
|
|
2.1(b)
|
|
Expense Policy
|
|
4.10(e)
|
|
Fair Market Value
|
|
4.9(c)(ii)
|
|
Federal Reserve
|
|
4.12
|
|
free writing prospectus
|
|
4.5(g)(i)
|
|
GAAP
|
|
2.1(a)
|
|
Governmental Entities
|
|
1.2(c)
|
|
Holder
|
|
4.5(k)(i)
|
|
Holders’ Counsel
|
|
4.5(k)(ii)
|
|
Indemnitee
|
|
4.5(g)(i)
|
|
Information
|
|
3.5(c)
|
iv
|
|
|
|
|
Investor
|
|
Preamble
|
|
Junior Stock
|
|
4.8(d)
|
|
knowledge of the Company
|
|
5.7(c)
|
|
Last Fiscal Year
|
|
2.1(b)
|
|
multiemployer plan
|
|
2.2(n)
|
|
officers
|
|
5.7(c)
|
|
Original Purchase Agreement
|
|
4.11
|
|
Other Senior Managers
|
|
4.10(b)
|
|
Parity Stock
|
|
4.8(d)
|
|
Pending Underwritten Offering
|
|
4.5(k)(viii)
|
|
Permitted Repurchases
|
|
4.8(a)(ii)
|
|
Piggyback Registration
|
|
4.5(a)(iv)
|
|
Plan
|
|
2.2(n)
|
|
Preferred Shares
|
|
Recitals
|
|
Preferred Stock
|
|
2.2(c)
|
|
Previously Disclosed
|
|
2.1(b)
|
|
Prior Year Bonus Compensation
|
|
4.10(c)(i)
|
|
Proprietary Rights
|
|
2.2(u)
|
|
Purchase
|
|
Recitals
|
|
Purchase Price
|
|
1.1
|
|
Purchased Securities
|
|
Recitals
|
|
Register, registered, and
registration
|
|
4.5(k)(ii)
|
|
Registrable Securities
|
|
4.5(k)(iv)
|
|
Registration Expenses
|
|
4.5(k)(v)
|
|
Regulatory Agreement
|
|
2.2(s)
|
|
road shows
|
|
4.5(c)(x)
|
|
Rules 144, 144A, 159A, 404 and 415
|
|
4.5(k)(vi)
|
|
SEC
|
|
2.1(b)
|
|
Securities Act
|
|
2.2(a)
|
|
SECURITIES ACT
|
|
4.2(b)
|
|
Selling Expenses
|
|
4.5(k)(vii)
|
|
Senior Executive Officers
|
|
4.10(a)
|
|
Share Dilution Amount
|
|
4.8(a)(ii)
|
|
Shelf Registration Statement
|
|
4.5(a)(ii)
|
|
Signing Date
|
|
2.1(a)
|
|
Special Registration
|
|
4.5(i)
|
|
subsidiary
|
|
5.7(a)
|
|
TARP
|
|
Recitals
|
|
Tax
|
|
2.2(o)
|
|
Transfer
|
|
4.4
|
|
U.S. Lobbying Policy
|
|
4.10(d)
|
|
under common control with
|
|
5.7(b)
|
|
Vested Benefits
|
|
4.10(a)
|
|
Warrant
|
|
Recitals
|
|
Warrant Shares
|
|
2.2(d)
|
v
SECURITIES PURCHASE
AGREEMENT , dated
January 15, 2009 (this “ Agreement ”),
between Bank of America Corporation, a Delaware corporation (the
“ Company ”), and the United States Department
of the Treasury (the “ Investor ”).
Recitals:
WHEREAS, the Investor may from time
to time agree to purchase shares of preferred stock and warrants
from eligible financial institutions under the Troubled Asset
Relief Program (“ TARP ”);
WHEREAS, the Company agrees to
expand the flow of credit to U.S. consumers and businesses on
competitive terms to promote the sustained growth and vitality of
the U.S. economy;
WHEREAS, the Company agrees to work
diligently, under existing programs, to modify the terms of
residential mortgages as appropriate to strengthen the health of
the U.S. housing market;
WHEREAS, the Company intends to
issue in a private placement 800,000 shares of its preferred stock
designated as “Fixed Rate Cumulative Perpetual Preferred
Stock, Series R” (the “ Preferred Shares
”) and a warrant to purchase 150,375,940 shares of its Common
Stock (“ Common Stock ”) (the “
Warrant ” and, together with the
Preferred Shares, the “ Purchased Securities ”),
and the Investor intends to purchase (the “ Purchase
”) from the Company the Purchased Securities under
TARP.
NOW, THEREFORE
, in consideration of the premises,
and of the representations, warranties, covenants and agreements
set forth herein, the parties agree as follows:
ARTICLE I
Purchase; Closing
1.1 Purchase . On the terms
and subject to the conditions set forth in this Agreement, the
Company agrees to sell to the Investor, and the Investor agrees to
purchase from the Company, at the Closing (as hereinafter defined),
the Purchased Securities for an aggregate purchase price of
$20,000,000,000 (the “ Purchase Price ”). For
the avoidance of doubt, the parties agree that the full Purchase
Price represents a capital contribution by the Investor solely in
exchange for the Purchased Securities.
1.2 Closing .
(a) On the terms and subject to the
conditions set forth in this Agreement, the closing of the Purchase
(the “ Closing ”) will take place at the offices
of Simpson Thacher & Bartlett LLP, 425 Lexington Avenue,
New York, New York 10017, at 9:00 a.m., New York time, on
January 16, 2009 or as soon as practicable thereafter, or at
such other place, time and date as shall be agreed between the
Company and the Investor. The time and date on which the Closing
occurs is referred to in this Agreement as the “ Closing
Date ”.
(b) Subject to the fulfillment or
waiver of the conditions to the Closing in this Section 1.2,
at the Closing the Company will deliver the Preferred Shares and
the Warrant, in each case as evidenced by one or more certificates
dated the Closing Date and bearing appropriate legends as
hereinafter provided for, in exchange for payment in full of the
Purchase Price by wire transfer of immediately available United
States funds to a bank account that has been designated by the
Company in writing to the Investor at least one business day prior
to the Closing Date.
(c) The respective obligations of
each of the Investor and the Company to consummate the Purchase are
subject to the fulfillment (or waiver by the Investor and the
Company, as applicable) prior to the Closing of the conditions that
(i) any approvals or authorizations of all United States and
other governmental, regulatory or judicial authorities
(collectively, “ Governmental Entities ”)
required for the consummation of the Purchase shall have been
obtained or made in form and substance reasonably satisfactory to
each party and shall be in full force and effect and all waiting
periods required by United States and other applicable law, if any,
shall have expired and (ii) no provision of any applicable
United States or other law and no judgment, injunction, order or
decree of any Governmental Entity shall prohibit the purchase and
sale of the Purchased Securities as contemplated by this
Agreement.
(d) The obligation of the Investor
to consummate the Purchase is also subject to the fulfillment (or
waiver by the Investor) at or prior to the Closing of each of the
following conditions:
(i) (A) the representations and
warranties of the Company set forth in (x) Section 2.2(g)
of this Agreement shall be true and correct in all respects as
though made on and as of the Closing Date, (y) Sections 2.2(a)
through (f) shall be true and correct in all material respects
as though made on and as of the Closing Date (other than
representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct in all material respects as of such other date) and
(z) Sections 2.2(h) through (v) (disregarding all
qualifications or limitations set forth in such representations and
warranties as to “materiality”, “Company Material
Adverse Effect” and words of similar import) shall be true
and correct as though made on and as of the Closing Date (other
than representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct as of such other date), except to the extent that the
failure of such representations and warranties referred to in this
Section 1.2(d)(i)(A)(z) to be so true and correct,
individually or in the aggregate, does not have and would not
reasonably be expected to have a Company Material Adverse Effect
and (B) the Company shall have performed in all material
respects all obligations required to be performed by it under this
Agreement at or prior to the Closing;
(ii) the Investor shall have
received a certificate signed on behalf of the Company by a senior
executive officer certifying to the effect that the conditions set
forth in Section 1.2(d)(i) have been satisfied;
2
(iii) the Company shall have duly
adopted and filed with the Secretary of State of the State of
Delaware the amendment to its certificate of incorporation (“
Charter ”) in substantially the form attached hereto
as Annex A (the “ Certificate of
Designations ”) and such filing shall have been
accepted;
(iv) (A) the Company shall have
effected such changes to its compensation, bonus, incentive and
other benefit plans, arrangements and agreements (including golden
parachute, severance and employment agreements) (collectively,
“ Benefit Plans ”) with respect to its Senior
Executive Officers and Other Senior Managers (and to the extent
necessary for such changes to be legally enforceable, each of its
Senior Executive Officers and Other Senior Managers shall have duly
consented in writing to such changes), as may be necessary, during
the period that the Investor owns any debt or equity securities of
the Company acquired pursuant to this Agreement or the Warrant, in
order to comply with Section 111(b) of the Emergency Economic
Stabilization Act of 2008 (“ EESA ”) as
implemented by guidance or regulation thereunder that has been
issued and is in effect as of the Closing Date, and
Section 4.10 of this Agreement, and (B) the Investor
shall have received a certificate signed on behalf of the Company
by a senior executive officer certifying to the effect that the
condition set forth in Section 1.2(d)(iv)(A) has been
satisfied;
(v) each of the Company’s
Senior Executive Officers and Other Senior Managers shall have
delivered to the Investor a written waiver in the form attached
hereto as Annex B releasing the Investor from any claims
that such Senior Executive Officer or Other Senior Managers may
otherwise have as a result of the issuance, on or prior to the
Closing Date, of any regulations which require the modification of,
and the agreement of the Company hereunder to modify, the terms of
any Benefit Plans with respect to its Senior Executive Officers and
Other Senior Managers, as applicable, to eliminate any provisions
of such Benefit Plans that would not be in compliance with the
requirements of Section 111(b) of the EESA as implemented by
guidance or regulation thereunder that has been issued and is in
effect as of the Closing Date and Section 4.10 of this
Agreement;
(vi) the Company shall have
delivered to the Investor a written opinion from counsel to the
Company (which may be internal counsel), addressed to the Investor
and dated as of the Closing Date, in substantially the form
attached hereto as Annex C ;
(vii) the Company shall have
delivered certificates in proper form or, with the prior consent of
the Investor, evidence of shares in book-entry form, evidencing the
Preferred Shares to Investor or its designee(s); and
(viii) the Company shall have duly
executed the Warrant in substantially the form attached hereto as
Annex D and delivered such executed Warrant to the Investor
or its designee(s).
3
1.3 Interpretation . When a
reference is made in this Agreement to “Recitals,”
“Articles,” “Sections,”
“Annexes” or “Schedules” such reference
shall be to a Recital, Article or Section of, or Annex or Schedule
to, this Agreement, unless otherwise indicated. The terms defined
in the singular have a comparable meaning when used in the plural,
and vice versa. References to “herein”,
“hereof”, “hereunder” and the like refer to
this Agreement as a whole and not to any particular section or
provision, unless the context requires otherwise. The table of
contents and headings contained in this Agreement are for reference
purposes only and are not part of this Agreement. Whenever the
words “include,” “includes” or
“including” are used in this Agreement, they shall be
deemed followed by the words “without limitation.” No
rule of construction against the draftsperson shall be applied in
connection with the interpretation or enforcement of this
Agreement, as this Agreement is the product of negotiation between
sophisticated parties advised by counsel. All references to
“$” or “dollars” mean the lawful currency
of the United States of America. Except as expressly stated in this
Agreement, all references to any statute, rule or regulation are to
the statute, rule or regulation as amended, modified, supplemented
or replaced from time to time (and, in the case of statutes,
include any rules and regulations promulgated under the statute)
and to any section of any statute, rule or regulation include any
successor to the section. References to a “ business
day ” shall mean any day except Saturday, Sunday and any
day on which banking institutions in the State of New York
generally are authorized or required by law or other governmental
actions to close.
ARTICLE II
Representations and
Warranties
2.1 Disclosure .
(a) “ Company Material
Adverse Effect ” means a material adverse effect on
(i) the business, results of operation or financial condition
of the Company and its consolidated subsidiaries taken as a whole;
provided , however , that Company Material Adverse
Effect shall not be deemed to include the effects of
(A) changes after the date of this Agreement (the “
Signing Date ”) in general business, economic or
market conditions (including changes generally in prevailing
interest rates, credit availability and liquidity, currency
exchange rates and price levels or trading volumes in the United
States or foreign securities or credit markets), or any outbreak or
escalation of hostilities, declared or undeclared acts of war or
terrorism, in each case generally affecting the industries in which
the Company and its subsidiaries operate, (B) changes or
proposed changes after the Signing Date in generally accepted
accounting principles in the United States (“ GAAP
”) or regulatory accounting requirements, or authoritative
interpretations thereof, (C) changes or proposed changes after
the Signing Date in securities, banking and other laws of general
applicability or related policies or interpretations of
Governmental Entities (in the case of each of these clauses (A),
(B) and (C), other than changes or occurrences to the extent
that such changes or occurrences have or would reasonably be
expected to have a materially disproportionate adverse effect on
the Company and its consolidated subsidiaries taken as a whole
relative to comparable U.S. banking or financial services
organizations), or (D) changes in the market price or trading
volume of the Common Stock or any other equity, equity-related or
debt securities of the Company or its consolidated subsidiaries (it
being understood and agreed that the exception set forth in this
clause (D) does not apply to the underlying reason giving rise
to or contributing to any such change); or (ii) the ability of
the Company to consummate the Purchase and the other transactions
contemplated by
4
this Agreement and the Warrant and perform its
obligations hereunder or thereunder on a timely basis.
(b) “ Previously
Disclosed ” means information set forth or incorporated
in the (i) Company’s Annual Report on Form 10-K for the
most recently completed fiscal year of the Company filed with the
Securities and Exchange Commission (the “ SEC ”)
prior to the Signing Date (the “ Last Fiscal Year
”) or in its other reports and forms filed with or furnished
to the SEC under Sections 13(a), 14(a) or 15(d) of the Securities
Exchange Act of 1934 (the “ Exchange Act ”) on
or after the last day of the Last Fiscal Year and prior to the
Signing Date or (ii) comparable reports and forms of Merrill
Lynch & Co., Inc.
2.2 Representations and
Warranties of the Company . Except as Previously Disclosed, the
Company represents and warrants to the Investor that as of the
Signing Date and as of the Closing Date (or such other date
specified herein):
(a) Organization, Authority and
Significant Subsidiaries . The Company has been duly
incorporated and is validly existing and in good standing under the
laws of its jurisdiction of organization, with the necessary power
and authority to own its properties and conduct its business in all
material respects as currently conducted, and except as has not,
individually or in the aggregate, had and would not reasonably be
expected to have a Company Material Adverse Effect, has been duly
qualified as a foreign corporation for the transaction of business
and is in good standing under the laws of each other jurisdiction
in which it owns or leases properties or conducts any business so
as to require such qualification; each subsidiary of the Company
that is a “significant subsidiary” within the meaning
of Rule 1-02(w) of Regulation S-X under the Securities Act of 1933
(the “ Securities Act ”) has been duly organized
and is validly existing in good standing under the laws of its
jurisdiction of organization. The Charter and bylaws of the
Company, copies of which have been provided to the Investor prior
to the Signing Date, are true, complete and correct copies of such
documents as in full force and effect as of the Signing
Date.
(b) Capitalization . The
authorized capital stock of the Company, and the outstanding
capital stock of the Company (including securities convertible
into, or exercisable or exchangeable for, capital stock of the
Company) as of the most recent fiscal month-end preceding the
Signing Date (the “ Capitalization Date ”) is
set forth on Schedule A . The outstanding shares of capital
stock of the Company have been duly authorized and are validly
issued and outstanding, fully paid and nonassessable, and subject
to no preemptive rights (and were not issued in violation of any
preemptive rights). Except as provided in the Warrant, as of the
Signing Date, the Company does not have outstanding any securities
or other obligations providing the holder the right to acquire
Common Stock that is not reserved for issuance as specified on
Schedule A , and the Company has not made any other
commitment to authorize, issue or sell any Common Stock. Since the
Capitalization Date, the Company has not issued any shares of
Common Stock, other than (i) shares issued upon the exercise
of stock options or delivered under other equity-based awards or
other convertible securities or warrants which were issued and
outstanding on the Capitalization Date and disclosed on Schedule
A and (ii) shares disclosed on Schedule A
.
5
(c) Preferred Shares . The
Preferred Shares have been duly and validly authorized, and, when
issued and delivered pursuant to this Agreement, such Preferred
Shares will be duly and validly issued and fully paid and
non-assessable, will not be issued in violation of any preemptive
rights, and will rank pari passu with or senior to all other
series or classes of preferred stock of the Company ( “
Preferred Stock ”), whether or not issued or
outstanding, with respect to the payment of dividends and the
distribution of assets in the event of any dissolution, liquidation
or winding up of the Company.
(d) The Warrant and Warrant
Shares . The Warrant has been duly authorized and, when
executed and delivered as contemplated hereby, will constitute a
valid and legally binding obligation of the Company enforceable
against the Company in accordance with its terms, except as the
same may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting the
enforcement of creditors’ rights generally and general
equitable principles, regardless of whether such enforceability is
considered in a proceeding at law or in equity (“
Bankruptcy Exceptions ”). The shares of Common Stock
issuable upon exercise of the Warrant (the “ Warrant
Shares ”) have been duly authorized and reserved for
issuance upon exercise of the Warrant and when so issued in
accordance with the terms of the Warrant will be validly issued,
fully paid and non-assessable.
(e) Authorization,
Enforceability .
(i) The Company has the corporate
power and authority to execute and deliver this Agreement and the
Warrant and to carry out its obligations hereunder and thereunder
(which includes the issuance of the Preferred Shares, Warrant and
Warrant Shares). The execution, delivery and performance by the
Company of this Agreement and the Warrant and the consummation of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary corporate action on the part of the
Company and its stockholders, and no further approval or
authorization is required on the part of the Company. This
Agreement is a valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
subject to the Bankruptcy Exceptions.
(ii) The execution, delivery and
performance by the Company of this Agreement and the Warrant and
the consummation of the transactions contemplated hereby and
thereby and compliance by the Company with the provisions hereof
and thereof, will not (A) violate, conflict with, or result in
a breach of any provision of, or constitute a default (or an event
which, with notice or lapse of time or both, would constitute a
default) under, or result in the termination of, or accelerate the
performance required by, or result in a right of termination or
acceleration of, or result in the creation of, any lien, security
interest, charge or encumbrance upon any of the properties or
assets of the Company or any Company Subsidiary under any of the
terms, conditions or provisions of (i) its organizational
documents or (ii) any note, bond, mortgage, indenture, deed of
trust, license, lease, agreement or other instrument or obligation
to which the Company or any Company Subsidiary is a party or by
which it or any Company Subsidiary may be bound, or to which the
Company or any Company Subsidiary or any of the properties or
assets of the Company or any
6
Company Subsidiary may be subject,
or (B) subject to compliance with the statutes and regulations
referred to in the next paragraph, violate any statute, rule or
regulation or any judgment, ruling, order, writ, injunction or
decree applicable to the Company or any Company Subsidiary or any
of their respective properties or assets except, in the case of
clauses (A)(ii) and (B), for those occurrences that, individually
or in the aggregate, have not had and would not reasonably be
expected to have a Company Material Adverse Effect.
(iii) Other than the filing of the
Certificate of Designations with the Secretary of State of the
State of Delaware, any current report on Form 8-K required to be
filed with the SEC, such filings and approvals as are required to
be made or obtained under any state “blue sky” laws and
such as have been made or obtained, no notice to, filing with,
exemption or review by, or authorization, consent or approval of,
any Governmental Entity is required to be made or obtained by the
Company in connection with the consummation by the Company of the
Purchase except for any such notices, filings, exemptions, reviews,
authorizations, consents and approvals the failure of which to make
or obtain would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect.
(f) Anti-takeover Provisions and
Rights Plan . The Board of Directors of the Company (the
“ Board of Directors ”) has taken all necessary
action to ensure that the transactions contemplated by this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby, including the exercise of the
Warrant in accordance with its terms, will be exempt from any
anti-takeover or similar provisions of the Company’s Charter
and bylaws, and any other provisions of any applicable
“moratorium”, “control share”, “fair
price”, “interested stockholder” or other
anti-takeover laws and regulations of any jurisdiction. The Company
has taken all actions necessary to render any stockholders’
rights plan of the Company inapplicable to this Agreement and the
Warrant and the consummation of the transactions contemplated
hereby and thereby, including the exercise of the Warrant by the
Investor in accordance with its terms.
(g) No Company Material Adverse
Effect . Since September 30, 2008, no fact, circumstance,
event, change, occurrence, condition or development has occurred
that, individually or in the aggregate, has had or would reasonably
be expected to have a Company Material Adverse Effect.
(h) Company Financial
Statements . Each of the consolidated financial statements of
the Company and its consolidated subsidiaries (collectively the
“ Company Financial Statements ”) included or
incorporated by reference in the Company Reports filed with the SEC
since December 31, 2006, present fairly in all material
respects the consolidated financial position of the Company and its
consolidated subsidiaries as of the dates indicated therein (or if
amended prior to the Signing Date, as of the date of such
amendment) and the consolidated results of their operations for the
periods specified therein; and except as stated therein, such
financial statements (A) were prepared in conformity with GAAP
applied on a consistent basis (except as may be noted therein),
(B) have been prepared from, and are in accordance with, the
books and records of the Company and the Company Subsidiaries and
(C)
7
complied as to form, as of their respective
dates of filing with the SEC, in all material respects with the
applicable accounting requirements and with the published rules and
regulations of the SEC with respect thereto.
(i) Reports .
(i) Since December 31, 2006,
the Company and each subsidiary of the Company (each a “
Company Subsidiary ” and, collectively, the “
Company Subsidiaries ”) has timely filed all reports,
registrations, documents, filings, statements and submissions,
together with any amendments thereto, that it was required to file
with any Governmental Entity (the foregoing, collectively, the
“ Company Reports ”) and has paid all fees and
assessments due and payable in connection therewith, except, in
each case, as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
As of their respective dates of filing, the Company Reports
complied in all material respects with all statutes and applicable
rules and regulations of the applicable Governmental Entities. In
the case of each such Company Report filed with or furnished to the
SEC, such Company Report (A) did not, as of its date or if
amended prior to the Signing Date, as of the date of such
amendment, contain an untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements
made therein, in light of the circumstances under which they were
made, not misleading, and (B) complied as to form in all
material respects with the applicable requirements of the
Securities Act and the Exchange Act. With respect to all other
Company Reports, the Company Reports were complete and accurate in
all material respects as of their respective dates. No executive
officer of the Company or any Company Subsidiary has failed in any
respect to make the certifications required of him or her under
Section 302 or 906 of the Sarbanes-Oxley Act of
2002.
(ii) The records, systems, controls,
data and information of the Company and the Company Subsidiaries
are recorded, stored, maintained and operated under means
(including any electronic, mechanical or photographic process,
whether computerized or not) that are under the exclusive ownership
and direct control of the Company or the Company Subsidiaries or
their accountants (including all means of access thereto and
therefrom), except for any non-exclusive ownership and non-direct
control that would not reasonably be expected to have a material
adverse effect on the system of internal accounting controls
described below in this Section 2.2(i)(ii). The Company
(A) has implemented and maintains disclosure controls and
procedures (as defined in Rule 13a-15(e) of the Exchange Act) to
ensure that material information relating to the Company, including
the consolidated Company Subsidiaries, is made known to the chief
executive officer and the chief financial officer of the Company by
others within those entities, and (B) has disclosed, based on
its most recent evaluation prior to the Signing Date, to the
Company’s outside auditors and the audit committee of the
Board of Directors (x) any significant deficiencies and
material weaknesses in the design or operation of internal controls
over financial reporting (as defined in Rule 13a-15(f) of the
Exchange Act) that are reasonably likely to adversely
affect
8
the Company’s ability to
record, process, summarize and report financial information and
(y) any fraud, whether or not material, that involves
management or other employees who have a significant role in the
Company’s internal controls over financial
reporting.
(j) No Undisclosed
Liabilities . Neither the Company nor any of the Company
Subsidiaries has any liabilities or obligations of any nature
(absolute, accrued, contingent or otherwise) which are not properly
reflected or reserved against in the Company Financial Statements
to the extent required to be so reflected or reserved against in
accordance with GAAP, except for (A) liabilities that have
arisen since the last fiscal year end in the ordinary and usual
course of business and consistent with past practice and
(B) liabilities that, individually or in the aggregate, have
not had and would not reasonably be expected to have a Company
Material Adverse Effect.
(k) Offering of Securities .
Neither the Company nor any person acting on its behalf has taken
any action (including any offering of any securities of the Company
under circumstances which would require the integration of such
offering with the offering of any of the Purchased Securities under
the Securities Act, and the rules and regulations of the SEC
promulgated thereunder), which might subject the offering, issuance
or sale of any of the Purchased Securities to Investor pursuant to
this Agreement to the registration requirements of the Securities
Act.
(l) Litigation and Other
Proceedings . Except (i) as set forth on Schedule B
or (ii) as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect,
there is no (A) pending or, to the knowledge of the Company,
threatened, claim, action, suit, investigation or proceeding,
against the Company or any Company Subsidiary or to which any of
their assets are subject nor is the Company or any Company
Subsidiary subject to any order, judgment or decree or
(B) unresolved violation, criticism or exception by any
Governmental Entity with respect to any report or relating to any
examinations or inspections of the Company or any Company
Subsidiaries.
(m) Compliance with Laws .
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, the Company
and the Company Subsidiaries have all permits, licenses,
franchises, authorizations, orders and approvals of, and have made
all filings, applications and registrations with, Governmental
Entities that are required in order to permit them to own or lease
their properties and assets and to carry on their business as
presently conducted and that are material to the business of the
Company or such Company Subsidiary. Except as set forth on
Schedule C , the Company and the Company Subsidiaries have
complied in all respects and are not in default or violation of,
and none of them is, to the knowledge of the Company, under
investigation with respect to or, to the knowledge of the Company,
have been threatened to be charged with or given notice of any
violation of, any applicable domestic (federal, state or local) or
foreign law, statute, ordinance, license, rule, regulation, policy
or guideline, order, demand, writ, injunction, decree or judgment
of any Governmental Entity, other than such noncompliance, defaults
or violations that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
Except for statutory or regulatory restrictions of general
application or as set forth on Schedule C , no Governmental
Entity has placed any restriction on the business or
9
properties of the Company or any Company
Subsidiary that would, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect.
(n) Employee Benefit Matters
. Except as would not reasonably be expected to have, either
individually or in the aggregate, a Company Material Adverse
Effect: (A) each “employee benefit plan” (within
the meaning of Section 3(3) of the Employee Retirement Income
Security Act of 1974, as amended (“ ERISA ”))
providing benefits to any current or former employee, officer or
director of the Company or any member of its “ Controlled
Group ” (defined as any organization which is a member of
a controlled group of corporations within the meaning of
Section 414 of the Internal Revenue Code of 1986, as amended
(the “ Code ”)) that is sponsored, maintained or
contributed to by the Company or any member of its Controlled Group
and for which the Company or any member of its Controlled Group
would have any liability, whether actual or contingent (each, a
“ Plan ”) has been maintained in compliance with
its terms and with the requirements of all applicable statutes,
rules and regulations, including ERISA and the Code; (B) with
respect to each Plan subject to Title IV of ERISA (including, for
purposes of this clause (B), any plan subject to Title IV of ERISA
that the Company or any member of its Controlled Group previously
maintained or contributed to in the six years prior to the Signing
Date), (1) no “reportable event” (within the
meaning of Section 4043(c) of ERISA), other than a reportable
event for which the notice period referred to in
Section 4043(c) of ERISA has been waived, has occurred in the
three years prior to the Signing Date or is reasonably expected to
occur, (2) no “accumulated funding deficiency”
(within the meaning of Section 302 of ERISA or
Section 412 of the Code), whether or not waived, has occurred
in the three years prior to the Signing Date or is reasonably
expected to occur, (3) the fair market value of the assets
under each Plan exceeds the present value of all benefits accrued
under such Plan (determined based on the assumptions used to fund
such Plan) and (4) neither the Company nor any member of its
Controlled Group has incurred in the six years prior to the Signing
Date, or reasonably expects to incur, any liability under Title IV
of ERISA (other than contributions to the Plan or premiums to the
PBGC in the ordinary course and without default) in respect of a
Plan (including any Plan that is a “ multiemployer
plan ”, within the meaning of Section 4001(c)(3) of
ERISA); and (C) each Plan that is intended to be qualified
under Section 401(a) of the Code has received a favorable
determination letter from the Internal Revenue Service with respect
to its qualified status that has not been revoked, or such a
determination letter has been timely applied for but not received
by the Signing Date, and nothing has occurred, whether by action or
by failure to act, which could reasonably be expected to cause the
loss, revocation or denial of such qualified status or favorable
determination letter.
(o) Taxes . Except as would
not, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect, (i) the Company and
the Company Subsidiaries have filed all federal, state, local and
foreign income and franchise Tax returns required to be filed
through the Signing Date, subject to permitted extensions, and have
paid all Taxes due thereon, and (ii) no Tax deficiency has
been determined adversely to the Company or any of the Company
Subsidiaries, nor does the Company have any knowledge of any Tax
deficiencies. “ Tax ” or “ Taxes
” means any federal, state, local or foreign income, gross
receipts, property, sales, use, license, excise, franchise,
employment, payroll, withholding, alternative or add on minimum, ad
valorem, transfer or excise tax, or any other tax, custom, duty,
governmental fee or other like assessment or charge of any kind
whatsoever, together with any interest or penalty, imposed by any
Governmental Entity.
10
(p) Properties and Leases .
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, the Company
and the Company Subsidiaries have good and marketable title to all
real properties and all other properties and assets owned by them,
in each case free from liens, encumbrances, claims and defects that
would affect the value thereof or interfere with the use made or to
be made thereof by them. Except as would not, individually or in
the aggregate, reasonably be expected to have a Company Material
Adverse Effect, the Company and the Company Subsidiaries hold all
leased real or personal property under valid and enforceable leases
with no exceptions that would interfere with the use made or to be
made thereof by them.
(q) Environmental Liability .
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect:
(i) there is no legal,
administrative, or other proceeding, claim or action of any nature
seeking to impose, or that would reasonably be expected to result
in the imposition of, on the Company or any Company Subsidiary, any
liability relating to the release of hazardous substances as
defined under any local, state or federal environmental statute,
regulation or ordinance, including the Comprehensive Environmental
Response, Compensation and Liability Act of 1980, pending or, to
the Company’s knowledge, threatened against the Company or
any Company Subsidiary;
(ii) to the Company’s
knowledge, there is no reasonable basis for any such proceeding,
claim or action; and
(iii) neither the Company nor any
Company Subsidiary is subject to any agreement, order, judgment or
decree by or with any court, Governmental Entity or third party
imposing any such environmental liability.
(r) Risk Management
Instruments . Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, all derivative instruments, including, swaps, caps,
floors and option agreements, whether entered into for the
Company’s own account, or for the account of one or more of
the Company Subsidiaries or its or their customers, were entered
into (i) only in the ordinary course of business, (ii) in
accordance with prudent practices and in all material respects with
all applicable laws, rules, regulations and regulatory policies and
(iii) with counterparties believed to be financially
responsible at the time; and each of such instruments constitutes
the valid and legally binding obligation of the Company or one of
the Company Subsidiaries, enforceable in accordance with its terms,
except as may be limited by the Bankruptcy Exceptions. Neither the
Company or the Company Subsidiaries, nor, to the knowledge of the
Company, any other party thereto, is in breach of any of its
obligations under any such agreement or arrangement other than such
breaches that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse
Effect.
(s) Agreements with Regulatory
Agencies . Except as set forth on Schedule D , neither
the Company nor any Company Subsidiary is subject to any material
cease-and-desist or other similar order or enforcement action
issued by, or is a party to any material written agreement, consent
agreement or memorandum of understanding with, or is a party to
any
11
commitment letter or similar undertaking to, or
is subject to any capital directive by, or since December 31,
2006, has adopted any board resolutions at the request of, any
Governmental Entity (other than the Appropriate Federal Banking
Agencies with jurisdiction over the Company and the Company
Subsidiaries) that currently restricts in any material respect the
conduct of its business or that in any material manner relates to
its capital adequacy, its liquidity and funding policies and
practices, its ability to pay dividends, its credit, risk
management or compliance policies or procedures, its internal
controls, its management or its operations or business (each item
in this sentence, a “ Regulatory Agreement ”),
nor has the Company or any Company Subsidiary been advised since
December 31, 2006 by any such Governmental Entity that it is
considering issuing, initiating, ordering, or requesting any such
Regulatory Agreement. The Company and each Company Subsidiary are
in compliance in all material respects with each Regulatory
Agreement to which it is party or subject, and neither the Company
nor any Company Subsidiary has received any notice from any
Governmental Entity indicating that either the Company or any
Company Subsidiary is not in compliance in all material respects
with any such Regulatory Agreement. “ Appropriate Federal
Banking Agency ” means the “appropriate Federal
banking agency” with respect to the Company or such Company
Subsidiaries, as applicable, as defined in Section 3(q) of the
Federal Deposit Insurance Act (12 U.S.C.
Section 1813(q)).
(t) Insurance . The Company
and the Company Subsidiaries are insured with reputable insurers
against such risks and in such amounts as the management of the
Company reasonably has determined to be prudent and consistent with
industry practice. The Company and the Company Subsidiaries are in
material compliance with their insurance policies and are not in
default under any of the material terms thereof, each such policy
is outstanding and in full force and effect, all premiums and other
payments due under any material policy have been paid, and all
claims thereunder have been filed in due and timely fashion,
except, in each case, as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect.
(u) Intellectual Property .
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, (i) the
Company and each Company Subsidiary owns or otherwise has the right
to use, all intellectual property rights, including all trademarks,
trade dress, trade names, service marks, domain names, patents,
inventions, trade secrets, know-how, works of authorship and
copyrights therein, that are used in the conduct of their existing
businesses and all rights relating to the plans, design and
specifications of any of its branch facilities (“
Proprietary Rights ”) free and clear of all liens and
any claims of ownership by current or former employees,
contractors, designers or others and (ii) neither the Company
nor any of the Company Subsidiaries is materially infringing,
diluting, misappropriating or violating, nor has the Company or any
or the Company Subsidiaries received any written (or, to the
knowledge of the Company, oral) communications alleging that any of
them has materially infringed, diluted, misappropriated or
violated, any of the Proprietary Rights owned by any other person.
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, to the
Company’s knowledge, no other person is infringing, diluting,
misappropriating or violating, nor has the Company or any or the
Company Subsidiaries sent any written communications since
January 1, 2006 alleging that any person has infringed,
diluted, misappropriated or violated, any of the Proprietary Rights
owned by the Company and the Company Subsidiaries.
12
(v) Brokers and Finders . No
broker, finder or investment banker is entitled to any financial
advisory, brokerage, finder’s or other fee or commission in
connection with this Agreement or the Warrant or the transactions
contemplated hereby or thereby based upon arrangements made by or
on behalf of the Company or any Company Subsidiary for which the
Investor could have any liability.
ARTICLE III
Covenants
3.1 Commercially Reasonable
Efforts . Subject to the terms and conditions of this
Agreement, each of the parties will use its commercially reasonable
efforts in good faith to take, or cause to be taken, all actions,
and to do, or cause to be done, all things necessary, proper or
desirable, or advisable under applicable laws, so as to permit
consummation of the Purchase as promptly as practicable and
otherwise to enable consummation of the transactions contemplated
hereby and shall use commercially reasonable efforts to cooperate
with the other party to that end.
3.2 Expenses . Unless
otherwise provided in this Agreement or the Warrant, each of the
parties hereto will bear and pay all costs and expenses incurred by
it or on its behalf in connection with the transactions
contemplated under this Agreement and the Warrant, including fees
and expenses of its own financial or other consultants, investment
bankers, accountants and counsel.
3.3 Sufficiency of Authorized
Common Stock; Exchange Listing .
(a) During the period from the
Closing Date until the date on which the Warrant has been fully
exercised, the Company shall at all times have reserved for
issuance, free of preemptive or similar rights, a sufficient number
of authorized and unissued Warrant Shares to effectuate such
exercise. Nothing in this Section 3.3 shall preclude the
Company from satisfying its obligations in respect of the exercise
of the Warrant by delivery of shares of Common Stock which are held
in the treasury of the Company. As soon as reasonably practicable
following the Closing, the Company shall, at its expense, cause the
Warrant Shares to be listed on the same national securities
exchange on which the Common Stock is listed, subject to official
notice of issuance, and shall maintain such listing for so long as
any Common Stock is listed on such exchange.
(b) If requested by the Investor,
the Company shall promptly use its reasonable best efforts to cause
the Preferred Shares to be approved for listing on a national
securities exchange as promptly as practicable following such
request.
3.4 Certain Notifications Until
Closing . From the Signing Date until the Closing, the Company
shall promptly notify the Investor of (i) any fact, event or
circumstance of which it is aware and which would reasonably be
expected to cause any representation or warranty of the Company
contained in this Agreement to be untrue or inaccurate in any
material respect or to cause any covenant or agreement of the
Company contained in this Agreement not to be complied with or
satisfied in any material respect and (ii) except as
Previously Disclosed, any fact, circumstance, event, change,
occurrence, condition or development of which the
13
Company is aware and which, individually or in
the aggregate, has had or would reasonably be expected to have a
Company Material Adverse Effect; provided , however ,
that delivery of any notice pursuant to this Section 3.4 shall
not limit or affect any rights of or remedies available to the
Investor; provided , further , that a failure to
comply with this Section 3.4 shall not constitute a breach of
this Agreement or the failure of any condition set forth in
Section 1.2 to be satisfied unless the underlying Company
Material Adverse Effect or material breach would independently
result in the failure of a condition set forth in Section 1.2
to be satisfied.
3.5 Access, Information and
Confidentiality .
(a) From the Signing Date until the
date when the Investor holds an amount of Preferred Shares having
an aggregate liquidation value of less than 10% of the Purchase
Price, the Company will permit the Investor and its agents,
consultants, contractors and advisors (x) acting through the
Appropriate Federal Banking Agency, to examine the corporate books
and make copies thereof and to discuss the affairs, finances and
accounts of the Company and the Company Subsidiaries with the
principal officers of the Company, all upon reasonable notice and
at such reasonable times and as often as the Investor may
reasonably request and (y) to review any information material
to the Investor’s investment in the Company provided by the
Company to its Appropriate Federal Banking Agency.
(b) From the Signing Date until the
date when the Investor holds an amount of Preferred Shares having
an aggregate liquidation value of less than 10% of the Purchase
Price, the Company will and will permit and will cause the Company
Subsidiaries to permit (x) the Investor and its agents,
consultants, contractors, (y) the Special Inspector General of
the Troubled Asset Relief Program, and (z) the Comptroller
General of the United States access to personnel and any books,
papers, records or other data, in each case, to the extent relevant
to ascertaining compliance with the financing terms and conditions;
provided that prior to disclosing any information pursuant to
clause (y) or (z), the Special Inspector General of the
Troubled Asset Relief Program and the Comptroller General of the
United States shall have agreed, with respect to documents obtained
under this agreement in furtherance of its function, to follow
applicable law and regulation (and the applicable customary
policies and procedures) regarding the dissemination of
confidential materials, including redacting confidential
information from the public version of its reports and soliciting
the input from the Company as to information that should be
afforded confidentiality, as appropriate.
(c) The Investor will use reasonable
best efforts to hold, and will use reasonable best efforts to cause
its agents, consultants, contractors, advisors, and United States
executive branch officials and employees, to hold, in confidence
all non-public records, books, contracts, instruments, computer
data and other data and information (collectively, “
Information ”) concerning the Company furnished or
made available to it by the Company or its representatives pursuant
to this Agreement (except to the extent that such information can
be shown to have been (i) previously known by such party on a
non-confidential basis, (ii) in the public domain through no
fault of such party or (iii) later lawfully acquired from
other sources by the party to which it was furnished (and without
violation of any other confidentiality obligation));
provided that nothing herein shall prevent the Investor from
disclosing any Information to the extent required by applicable
laws or regulations or by any subpoena or similar legal process.
The Investor understands that the Information may contain
commercially
14
sensitive confidential information entitled to
an exception from a Freedom of Information Act request.
(d) The Investor represents that it
has been informed by the Special Inspector General of the Troubled
Asset Relief Program and the Comptroller General of the United
States that they, before making any request for access or
information pursuant to their audit function under this Agreement,
will establish a protocol to avoid, to the extent reasonably
possible, duplicative requests pursuant to this Agreement. Nothing
in this section shall be construed to limit the authority that the
Special Inspector General of the Troubled Asset Relief Program or
the Comptroller General of the United States have under
law.
3.6 Internal Controls
.
(a) The Company agrees to
(i) promptly establish appropriate internal controls with
respect to compliance with each of the Company’s covenants
and agreements set forth in Sections 4.8 through 4.12;
(ii) report to Investor on a quarterly basis regarding the
implementation of those controls and the Company’s compliance
(including any instances of non-compliance) with such covenants and
agreements; and (iii) provide a signed certification from a
senior officer to Investor that such report is accurate to the best
of his or her knowledge, which certification shall be made subject
to the requirements and penalties set forth in Title 18, United
States Code, Section 1001.
(b) The Company agrees to
(i) use its reasonable best efforts to account for its use of
the Purchase Price, (ii) set up internal controls with respect
to compliance with applicable requirements regarding the use of the
Purchase Price, (iii) report to Investor on a quarterly basis
until all of the Purchase Price has been accounted for regarding
the use of the Purchase Price, the implementation of those controls
and the Company’s compliance (including any instances of
non-compliance) with such requirements applicable to the Purchase
Price; and (iv) provide a signed certification from a senior
officer to Investor that such report is accurate to the best of his
or her knowledge, which certification shall be made subject to the
requirements and penalties set forth in Title 18, United States
Code, Section 1001.
(c) The Company’s management
shall monitor the use of the Purchase Price and will report to the
Company’s Board of Directors on a quarterly basis until all
of the Purchase Price has been accounted for regarding the use of
the Purchase Price.
ARTICLE IV
Additional
Agreements
4.1 Purchase for Investment .
The Investor acknowledges that the Purchased Securities and the
Warrant Shares have not been registered under the Securities Act or
under any state securities laws. The Investor (a) is acquiring
the Purchased Securities pursuant to an exemption from registration
under the Securities Act solely for investment with no present
intention to distribute them to any person in violation of the
Securities Act or any applicable U.S. state securities laws,
(b) will not sell or otherwise dispose of any of the Purchased
Securities or the Warrant Shares, except in compliance with the
registration requirements or exemption provisions of the Securities
Act and any applicable U.S. state securities laws, and (c) has
such
15
knowledge and experience in financial and
business matters and in investments of this type that it is capable
of evaluating the merits and risks of the Purchase and of making an
informed investment decision.
4.2 Legends .
(a) The Investor agrees that all
certificates or other instruments representing the Warrant and the
Warrant Shares will bear a legend substantially to the following
effect:
“THE SECURITIES REPRESENTED BY
THIS INSTRUMENT HAVE N